Literature DB >> 16848414

Dendritic iodinated contrast agents with PEG-cores for CT imaging: synthesis and preliminary characterization.

Yanjun Fu1, Danute E Nitecki, David Maltby, Gerhard H Simon, Kirill Berejnoi, Hans-Juergen Raatschen, Benjamin M Yeh, David M Shames, Robert C Brasch.   

Abstract

The purpose of this study was to design, synthesize, and initially characterize a representative set of novel constructs for large-molecular radiographic/computed tomography (CT) contrast agents, intended for a primarily intravascular distribution. A new assembly of well-known and biocompatible components consists of paired, symmetrical dendritic polylysines initiated from both ends of a poly(ethylene glycol) (PEG) core, yielding an array of multiple free amino groups to which were conjugated highly soluble and stable triiodophthalamide ("triiodo") moieties. An array of six dendritic contrast agents was synthesized originally, using three different PEG cores (3, 6, 12 kDa) with t-Boc lysine-generated dendrimer "amplifiers" (from three to five generations) containing 16 to 64 amino groups for conjugation with reactive triiodo moieties. A clinically used, nonionic, small molecular CT contrast agent, iobitridol, was derivatized via a hydroxyl protection/deprotection strategy, introducing a new carboxyl group available for conjugation to the lysine amino groups of dendrimers. Final products were purified by size exclusion chromatography and characterized by NMR, UV, HPLC, and elemental analysis. Preliminary evaluations were conducted for physicochemical characterization and in vivo CT contrast enhancement in a rat model. All six iodinated PEG-core dendrimer conjugates were synthesized in good yields, with a high degree of size monodispersity, large apparent molecular weight, favored physicochemical properties. A representative compound, PEG12000-carbamate-Gen4-IOB conjugate, 27% (w%) rich in iodine, demonstrated a desirable strong and persistent intravascular enhancement with a monoexponential blood half-life of approximately 35 min assayed by dynamic CT imaging and also showed high water solubility (>550 mg/mL at 25 degrees C), large apparent molecular size (comparable to a 143-kDa protein), high hydrophilicity (butanol-water partition coefficient 0.015), and stability to autoclaving conditions. This study showed the synthetic feasibility, desired basic characteristics, and potential utility for CT contrast enhancement achieved with a new type of iodinated, large-molecular PEG-core dendritic construct. Further development of this class of macromolecular contrast agents will be required to define the optimal formulation, pharmacology, safety profile, and the full range of diagnostic applications including tumor microvascular quantitative characterization by CT imaging.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16848414     DOI: 10.1021/bc060019c

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  22 in total

1.  Evaluation of a novel macromolecular cascade-polymer contrast medium for dynamic contrast-enhanced MRI monitoring of antiangiogenic bevacizumab therapy in a human melanoma model.

Authors:  Clemens C Cyran; Yanjun Fu; Victor Rogut; Bundit Chaopathomkul; Michael F Wendland; David M Shames; Robert C Brasch
Journal:  Acad Radiol       Date:  2013-10       Impact factor: 3.173

Review 2.  Nanotechnology for computed tomography: a real potential recently disclosed.

Authors:  Nicolas Anton; Thierry F Vandamme
Journal:  Pharm Res       Date:  2013-07-30       Impact factor: 4.200

3.  Biodegradable iodinated polydisulfides as contrast agents for CT angiography.

Authors:  Erlei Jin; Zheng-Rong Lu
Journal:  Biomaterials       Date:  2014-04-24       Impact factor: 12.479

Review 4.  Dendrimer nanoscaffolds for potential theranostics of prostate cancer with a focus on radiochemistry.

Authors:  Su-Tang Lo; Amit Kumar; Jer-Tsong Hsieh; Xiankai Sun
Journal:  Mol Pharm       Date:  2013-01-24       Impact factor: 4.939

5.  Hepatic fibrosis: evaluation with semiquantitative contrast-enhanced CT.

Authors:  Vanja Varenika; Yanjun Fu; Jacquelyn J Maher; Dongwei Gao; Sanjay Kakar; Miguel C Cabarrus; Benjamin M Yeh
Journal:  Radiology       Date:  2012-11-20       Impact factor: 11.105

6.  Development and application of a multimodal contrast agent for SPECT/CT hybrid imaging.

Authors:  Jason M Criscione; Lawrence W Dobrucki; Zhen W Zhuang; Xenophon Papademetris; Michael Simons; Albert J Sinusas; Tarek M Fahmy
Journal:  Bioconjug Chem       Date:  2011-09-06       Impact factor: 4.774

Review 7.  Opportunities for new CT contrast agents to maximize the diagnostic potential of emerging spectral CT technologies.

Authors:  Benjamin M Yeh; Paul F FitzGerald; Peter M Edic; Jack W Lambert; Robert E Colborn; Michael E Marino; Paul M Evans; Jeannette C Roberts; Zhen J Wang; Margaret J Wong; Peter J Bonitatibus
Journal:  Adv Drug Deliv Rev       Date:  2016-09-09       Impact factor: 15.470

8.  Poly(ethylene glycol)-poly(ε-caprolactone) iodinated nanocapsules as contrast agents for X-ray imaging.

Authors:  François Hallouard; Stéphanie Briançon; Nicolas Anton; Xiang Li; Thierry Vandamme; Hatem Fessi
Journal:  Pharm Res       Date:  2013-04-26       Impact factor: 4.200

Review 9.  X-ray-computed tomography contrast agents.

Authors:  Hrvoje Lusic; Mark W Grinstaff
Journal:  Chem Rev       Date:  2012-12-05       Impact factor: 60.622

10.  Polymer platforms for drug delivery and biomedical imaging.

Authors:  Zheng-Rong Lu; Furong Ye; Anagha Vaidya
Journal:  J Control Release       Date:  2007-06-27       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.